Profound Medical — Third Quarter 2026 Earnings Summary

Financial Performance

• Preliminary unaudited Q3 2026 total revenue is expected to range between $9.8 million and $10.0 million.
• Year-over-year revenue growth is expected to increase approximately 85% to 89% compared to $5.3 million in Q3 2025.
• Sequential quarter-over-quarter growth is expected to increase approximately 292% to 300% compared to $2.5 million in Q2 2026.
• Q3 2026 gross margin is expected to exceed 70%.
• Expected revenue is approximately 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.

Guidance and Future Outlook

• The company anticipates record-breaking quarterly revenue exceeding current Wall Street expectations.
• Management remains focused on supporting customer adoption, increasing utilization of the installed base, and building a profitable growth company over the long term.
• Full Q3 2026 financial results will be reported after market close on November 5, 2026.

Business Segments and Product Lines

• Growth reflects increased commercial activity across the installed base and new customer accounts.
• Flagship platform TULSA-PRO enables MRI-guided, incision-free prostate ablation and is cleared in the US, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE.
• Sonalleve is commercialized for MRI-guided therapy for bone metastases, desmoid tumors, osteoid osteoma, uterine fibroids, and adenomyosis; it is approved by the FDA as HDE in the US and cleared or approved in Europe, Canada, China, and Saudi Arabia.
• The company is exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Market and Competitive Landscape

• Technologies are approved across major global markets.
• The company is advancing MRI-guided therapy to expand access to precise, personalized, and incision-free treatment options worldwide.

Risks and Challenges

• Preliminary figures are unaudited and actual revenues may differ.
• Forward-looking statements regarding efficacy, preliminary revenues, gross margins, and future financial results are subject to known and unknown risk factors, including medical device industry risks, regulatory approvals, reimbursement, economic factors, equity market conditions, growth risks, and competition.
• Actual results may vary materially from projections due to numerous risks and uncertainties.

Management Commentary and Tone

• CEO Arun Menawat described the expected revenue increase as a "historic milestone" reflecting strong commercial momentum.
• Management expressed confidence that the third quarter represents an important step in the continued expansion of the commercial business.
• The tone emphasizes strong commercial activity and a focus on long-term profitability.

Other Key Points

• A conference call to review financial results and discuss business developments is scheduled for Thursday, November 5, 2026, at 4:30 p.m. ET.
• The call will be live and archived on the Company's website in the Investors section.
• Bloomberg consensus estimates used for comparison were compiled as of October 7, 2026, at 9:02 a.m. ET.